Corpus Intelligence IC Memo — KOHALA HOSPITAL 2026-04-26 09:36 UTC
IC Memo — KOHALA HOSPITAL
Investment Committee Memorandum | HI | 25 beds | Grade D | EBITDA uplift $1.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

KOHALA HOSPITAL

CCN 121302 | HAWAII, HI | 25 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

KOHALA HOSPITAL is a 25-bed safety-net/medicaid heavy in HAWAII, HI with $19.7M in net patient revenue and a 10.2% operating margin. The hospital serves a payer mix of 7.5% Medicare, 70.5% Medicaid, and 22.0% commercial.

Thesis: Turnaround. Our ML models identify $1.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 10.2% to 17.5% (+736bps).

Net Revenue HCRIS$19.7M
Current EBITDA COMPUTED$2.0M
Operating Margin COMPUTED10.2%
Occupancy HCRIS79.8%
Revenue / Bed COMPUTED$787K
Net-to-Gross HCRIS78.9%
Distress Probability ML62.5%

2. Market Context & Competitive Position

26
HI Hospitals
-14.7%
State Median Margin
2513
Comparable Hospitals

HI has 26 Medicare-certified hospitals with a median operating margin of -14.7%. The target's margin of 10.2% places it above the state median. Among 2513 size-comparable peers (12-50 beds), the median margin is -6.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-50), prioritizing same-state peers. 2513 hospitals in the comp set.

HospitalStateBedsRevenueMargin
KOHALA HOSPITAL (Target)HI25$19.7M10.2%
DANA-FARBER CANCER INSTITUTEMA30$1.88B-35.1%
FRED HUTCHINSON CANCER CENTERWA20$1.17B-50.0%
MERCY WALWORTH HOSPITALWI25$616.4M4.4%
MOUNTAIN VIEW HOSPITALID43$382.5M8.7%
WISE HEALTH SYSTEM - PARKWAYTX36$361.0M-15.5%
CORYELL MEMORIAL HOSPITALTX25$305.9M-1.5%
VALLEY VIEW HOSPITALCO31$285.3M-3.1%
TAHOE FOREST HOSPITALCA25$264.3M13.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$413K+210bp18mo
Cost to Collect4.5%2.5%$393K+200bp12mo
Denial Rate Reduction12.0%6.5%$389K+198bp12mo
A/R Days Reduction5200.0%3800.0%$239K+122bp9mo
Clean Claim Rate88.0%96.0%$13K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$413K
Cost to Collect
$393K
Denial Rate Reduction
$389K
A/R Days Reduction
$239K
Clean Claim Rate
$13K
Total EBITDA Uplift$1.4M
Current EBITDA$2.0M
+ RCM Uplift+$1.4M
Pro Forma EBITDA$3.4M
Current Margin10.2%
Pro Forma Margin17.5%
WC Released (1x)$755K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$3.1M$27.7M9.00x55.2%
Base (11x exit)10.0x11.0x$3.1M$31.4M10.22x59.2%
Bull Case9.0x11.0x$2.8M$37.2M13.45x68.2%
Bull (12x exit)9.0x12.0x$2.8M$41.4M14.97x71.8%
Bear Case11.0x10.0x$3.4M$19.4M5.74x41.9%
Bear (11x exit)11.0x11.0x$3.4M$22.5M6.64x46.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (70.5%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 62.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 2513 hospitals with 12-50 beds
  • Same-state prioritization (n=7)
  • Comp margins: P25=-18.7% / P50=-6.3% / P75=4.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.